Related Experiment Video
Updated: Jun 26, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.5K
[Anthracycline-induced Heart Failure: Treatment and Recovery Prospects]
M V Vitsenya1, A V Potekhina1, A Yu Filatova1
1Chazov National Medical Research Center of Cardiology, Moscow.
Kardiologiia
|May 14, 2024
Summary
Anthracycline chemotherapy can cause heart failure even in breast cancer patients with low cardiovascular risk. This case highlights the importance of monitoring cardiac function during cancer treatment.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Anthracyclines are effective chemotherapy agents for breast cancer.
- Cardiotoxicity is a known side effect of anthracycline therapy.
- Assessing cardiovascular risk is crucial in cancer patients undergoing treatment.
Purpose of the Study:
- To report a case of heart failure in a breast cancer patient receiving anthracycline therapy.
- To highlight the potential for cardiotoxicity in patients with initially low cardiovascular risk.
- To emphasize the need for vigilant cardiac monitoring during antitumor therapy.
Main Methods:
- Clinical case presentation.
- Review of patient's medical history and treatment regimen.
- Cardiovascular assessment and monitoring.
Main Results:
- The patient developed heart failure during anthracycline-containing antitumor therapy.
- The patient had an initially low risk for cardiovascular complications.
- Cardiac dysfunction occurred despite a low-risk profile.
Conclusions:
- Anthracycline therapy can precipitate heart failure, even in patients considered low risk.
- Early detection and management of cardiotoxicity are essential in breast cancer patients.
- This case underscores the importance of comprehensive cardiac surveillance in oncology.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
573
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
573
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:22Heart Failure Drugs: Diuretics
367
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
367
01:20Exercise and Cardiovascular Response
791
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
791
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K